Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
2024年4月19日 - 7:10PM
Alvotech signs U.S. agreement to expand access for newly approved
high-concentration interchangeable biosimilar to Humira®
(adalimumab)
- Alvotech, in agreement with Teva Pharmaceuticals, has signed an
agreement with a strategic partner to bring to the U.S. market the
newly FDA approved high-concentration interchangeable biosimilar to
Humira®
- The agreement broadens patient access and further commitment to
availability of vital biologics in the U.S. and globally
Alvotech (NASDAQ: ALVO), a global biotech company specializing
in the development and manufacture of biosimilar medicines for
patients worldwide, announced today a long-term agreement with a
strategic partner to further enhance access to Adalimumab-ryvk in
the U.S. market, the newly U.S. Food and Drug Administration (FDA)
approved high-concentration interchangeable biosimilar to
Humira.
“This new partnership agreement supports our financial guidance
and reflects Alvotech’s strong commitment to increasing patient
access to more affordable healthcare,” said Robert Wessman,
Chairman and CEO of Alvotech.
The current multi-product commercialization partnership between
Teva Pharmaceuticals and Alvotech remains unchanged and Teva will
continue to commercialize adalimumab-ryvk under the SIMLANDI® brand
in the U.S.
Use of TrademarksHumira® is a registered
trademark of AbbVie Biotechnology Ltd.
About AlvotechAlvotech is a biotech company,
founded by Robert Wessman, focused solely on the development and
manufacture of biosimilar medicines for patients worldwide.
Alvotech seeks to be a global leader in the biosimilar space by
delivering high quality, cost-effective products, and services,
enabled by a fully integrated approach and broad in-house
capabilities. Alvotech’s current pipeline includes eight disclosed
biosimilar candidates aimed at treating autoimmune disorders, eye
disorders, osteoporosis, respiratory disease, and cancer. Alvotech
has formed a network of strategic commercial partnerships to
provide global reach and leverage local expertise in markets that
include the United States, Europe, Japan, China, and other Asian
countries and large parts of South America, Africa and the Middle
East. Alvotech’s commercial partners include Teva Pharmaceuticals,
a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA
Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma
(EEA, UK, Switzerland, Canada, Australia and New Zealand),
Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South
Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River
Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong,
Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and
Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi
Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs,
Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co.,
Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each
commercial partnership covers a unique set of product(s) and
territories. Except as specifically set forth therein, Alvotech
disclaims responsibility for the content of periodic filings,
disclosures and other reports made available by its partners. For
more information, please visit www.alvotech.com. None of the
information on the Alvotech website shall be deemed part of this
press release.